Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Which patients should we treat beyond progression and when should we stop?

Do we have clinical or radiological biomarkers to guide us?

Date

16 Sep 2024

Session

Which patients should we treat beyond progression and when should we stop?

Topics

Translational Research;  Multi-Disciplinary and Multi-Professional Cancer Care;  Immunotherapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Roberto Ferrara

Authors

R. Ferrara

Author affiliations

  • Thoracic Oncology Unit, UniSR - Università Vita e Salute San Raffaele Milano, 20132 - Milan/IT

Resources

This content is available to ESMO members and event participants.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.